Remove 2025 Remove Hospitals Remove Insurance Coverage and Processing
article thumbnail

NHC Submits Comments on CMS’ Proposed Rule on Marketplace Integrity and Affordability

Putting Patients First Blog

While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.

article thumbnail

Flu Vaccines Are a Go

Pharmacy Times

That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Abigail Beaney July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The new legislation will reduce the time it takes for patients to receive these therapies from months to days. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

Questions Patient Access Leaders Should Be Asking About AI (But Aren’t)

Pharmaceutical Commerce

We talked about the many closed-door conversations happening during vendor evaluations, RFP processes, or internal strategy meetings and identified some core questions access experts should be asking teams—internal or external. Look for a vendor with clear escalation processes when AI reaches its limits.

article thumbnail

NHC Reconciliation Letter to Congress on One Big Beautiful Bill Act

Putting Patients First Blog

It will also negatively affect access to coverage and care for people that obtain their health coverage through the ACA Marketplace and Medicare. The proposed reconciliation bill heightens the risk that millions of Americans will lose access to care and coverage by shifting even more Medicaid costs to the states.

article thumbnail

Apertura signs multiple licensing agreements for TfR1 CapX tech

Pharmaceutical Technology

August 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook TfR1 CapX is an intravenously administered AAV capsid that targets the human transferrin receptor. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: Nekrasov Eugene/Shutterstock.com.

article thumbnail

ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture

Pharmaceutical Technology

By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. A first-in-human Phase I study involving patients with relapsed or refractory B-cell lymphoma is expected to commence using AVC-203 in the second half of 2025.